Last Updated : December 25, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Mictoryl | Propiverine hydrochloride | Overactive bladder (OAB) | Reimburse with clinical criteria and/or conditions | Complete | ||
Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Reimburse | Complete | ||
Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Withdrawn | |||
Minjuvi | tafasitamab | Diffuse large B-cell lymphoma (DLBCL) | Do not reimburse | Complete | ||
Monoferric | Iron (III) Isomaltoside 1000 | iron deficiency anemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Monoprost | latanoprost | glaucoma and ocular hypertension | Reimburse with clinical criteria and/or conditions | Complete | ||
Movapo | apomorphine hydrochloride | Parkinson's disease | Reimburse with clinical criteria and/or conditions | Complete | ||
Mozobil | Plerixafor | Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma | Do not list | Complete | ||
Multaq | Dronedarone hydrochloride | Atrial fibrillation | Do not list | Complete | ||
Mvasi | Bevacizumab | mCRC NSCLC Biosimilar | N/A | Complete |